Skip Nav Destination
Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
Mol Cancer Ther (2013) 12 (11_Supplement): A275.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
- Jong‐Hoon Scott Lee
- Thanh‐Trang Vo
- David A. Fruman
British Journal of Clinical Pharmacology (2016) 82 (5): 1213.
- Zehua Zhu
- Hadrien G Golay
- David A Barbie
Pharmacogenomics (2014) 15 (11): 1507.